B:2a:P1.5 Meningococcal Strains Likely Arisen from Capsular Switching Event Still Spreading in Spain

Castilla, Jesús; Vázquez, Julio A.; Salcedo, Celia; Cenoz, Manuel García; Irure, José Javier García; Torroba, L; Beristaín, Xabier; Abad, Raquel; Barricarte, Aurelio

doi:10.1128/jcm.01495-08

Cited by 21 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This sequence has subsequently been found in a large group of isolates of the B:2a:P1.5 phenotype, mostly isolated in Spain from 2002 to 2008, and belonging to the ST-11 cc. These may have arisen by horizontal transfer of the capsular operon (36). In the majority of isolates analyzed, the nadA gene was inactivated by frameshift mutations.…”

Section: Resultsmentioning

confidence: 99%

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

Bambini¹,

Chiara²,

Muzzi³

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

c Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/.

show abstract

Section: Resultsmentioning

confidence: 99%

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

Bambini¹,

Chiara²,

Muzzi³

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…11 Among the targeted age groups, the incidence of meningococcal C disease decreased conjugated meningococcal C vaccine. 9,10 In contrast, capsular switching has not been observed following such immunization in England. 11 Thus, potential replacement of N. meningitidis serogroups following wide acceptance of the quadrivalent (serogroups A, C, W-135, Y) conjugate vaccine may occur and should be monitored.…”

Section: The Bacteria and Cofactors Of Invasive Diseasementioning

confidence: 91%

“…Will vaccination drive capsular switching (e.g., serogroup C to B or other nonvaccine serogroups) as was seen with pneumococcal vaccines 80 and which has been suggested in some clinical isolates following the introduction of routine meningococcal C vaccination. 81,82 What immunization schedule is the most effective and cost-acceptable? This last issue has been the recent subject of debate.…”

Section: Challengesmentioning

confidence: 99%

Meningococcal disease: The advances and challenges of meningococcal disease prevention

Yogev¹,

Tan²

2011

Human Vaccines

View full text Add to dashboard Cite

Vaccination as a means to prevent meningococcal disease caused by Neisseria meningitidis is critical given the abrupt onset and rapid progression of this disease. Five serogroups--A, B, C, W-135, and Y--are responsible for the majority of cases. In developed countries, infants have the greatest risk of disease, with a smaller secondary peak observed in late adolescence. Vaccines utilizing the polysaccharide capsule are poorly immunogenic in young children but can reduce the incidence of meningococcal carriage in high risk groups. In contrast, protein conjugate vaccines to polysaccharide capsules A, C, W-135, and Y have broadened the population protection from disease but their effect on meningococcal carriage and transmission is yet unknown except for monovalent meningococcal C conjugate that has been shown to reduce carriage. Challenges remain in providing direct protection to infants and protection against meningococcal B disease. To date, outer membrane vesicle vaccines have been used to control meningococcal B disease in epidemic settings and vaccine candidates against subcapsular antigens are in development, but a vaccine that confers long-lasting protection is unavailable.

show abstract

“…The L2 Spanish strains described in the present study are B:2a:P1.5 isolates. It is likely that they derive from the Spanish meningococcal serogroup C:2a:P1.5 strain, after capsular switching event from serogroup C to B [30,31]. Some of these Spanish C:2a:P1.5 isolates were characterized by the presence of the insertion sequence IS1301 in the capsular locus, between the sia and ctr operons.…”

Section: Discussionmentioning

confidence: 97%